Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25621565.
- Also identified by DOI 10.7554/eLife.04586 and PMC identifier 4383318.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The Willingham et al., 2012, published in PNAS in 2012. The key experiments being replicated are those reported in Figure 6A-C and Table S4. In these experiments, Willingham et al., 2012 test the safety and efficacy of anti-CD47 antibody treatment in immune competent mice utilizing a syngeneic model of mammary tumor growth in FVB mice. The Reproducibility Project: Cancer Biology is a collaboration between the eLife.
Medical subject headings
- Antigens, Differentiation
- CD47 Antigen
- Molecular Targeted Therapy
- Neoplasms
- Receptors, Immunologic